IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Timo Kars van den Berg et al.	Attorney Docket No. 080743235001
Serial No.:	10/007,275	
Filed:	October 26, 2001	
For:	METHOD FOR INHIBITING CELL FUNCTIONING FOR USE IN ANTI-INFLAMMATORY AND ANTI-TUMOR THERAPIES	
Examiner:	Yaen, Christopher H.	
Group Art Unit:	1642	
Confirmation No.:	5284	

AMENDMENTS TO THE SPECIFICATION

Amend paragraph 0027 to read as follows:

The rat macrophage cell line NR8383 (Adams et al. 1998) are cultured at a density of 0.25 x 10^6 cells/ml in a 96-well cell culture plate in RPMI-1640 medium containing 2% fetal calf serum and 2 mM glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin. This is performed in the presence (or absence) of anti-SIRP Fab-fragments (ED9 or ED17; 40 μg/ml) or control Fab-fragments (OX41; 40 μg/ml). After 24 h ^{3}H-thymidine (1 μCi/well) is added and the cells are incubated for another 6 hours. The cells are harvested using a cell harvester and cell incorporated radioactivity is determined in a Micro-ß-plate reader. The mean results are shown ~~in Table 1~~ below in Table 1:

Table 1

Treatment	Mean (in c.p.m.)	SD (standard dev.)
control	132783	2730
ED17 Fab	6845	197
OX41 Fab	154889	8528

A1 Conclude

Amend paragraph 0029 to read as follows:

To examine the effects of ED9 or ED17 Fab on myeloid cell division, NR8383 cells are assayed as described in the macrophage division test. (Note to Examiner - previous underline is in original document and is not part of this amendment.) As illustrated in Table 1 ~~table 1~~, ED 17 ~~ED~~ strongly inhibits division (analyzed by thymidine incorporation), whereas OX41 Fab has little effect.

A2